Kunsheng Biology (01877.HK) announced its interim results, with a net loss attributable to shareholders of approximately 413 million yuan, a year-on-year decrease of about 36%.

The Zhitong Finance and Economics APP reported that Junshi Bio(01877.HK) announced its mid-term performance for 2025. The operating income is around 1.168 billion yuan, an increase of 48.64% year-on-year; the net loss attributable to the shareholders of the listed company is about 413 million yuan, narrowing by approximately 36% year-on-year; the basic loss per share is 0.42 yuan.